<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826616</url>
  </required_header>
  <id_info>
    <org_study_id>1672sdd</org_study_id>
    <nct_id>NCT02826616</nct_id>
  </id_info>
  <brief_title>Effect of Trimetazidine During the Primary PCI on Cardiac Function in Patients With ST-elevation Myocardial Infarction</brief_title>
  <official_title>Chinese People's Liberation Army General Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giving preoperative loading dose of 60mg of trimetazidine can safely and effectively reduce
      the PCI-related myocardial damage for the patients undergoing selective PCI. but the effect
      of Trimetazidine during the primary PCI on cardiac function in patients with ST-elevation
      myocardial infarction is not sure. this study aim to study the effect of Trimetazidine during
      the primary PCI on cardiac function in patients with ST-elevation myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will enroll 240 patients with STEMI who were admitted to the Chinese PLA
      General Hospital between Januay 2017 and August 2017. STEMI was defined as typical chest pain
      lasting 30 min within the previous 12 h, a clear ST-segment elevation of N0.1 mV in ≥2
      contiguous electrocardiographic leads, and elevated blood levels of troponin T. We randomly
      assign eligible patients in a 1:1 ratio to either 60mg of trimetazidine or oral placebo befor
      PCI. Trimetazidine group will accept 20mg of trimetazidine for 12 months after PCI and active
      Comparator will be given placebo for 12 months after PCI.

      Primary end point of the study was the area of viable myocardium coming from MR delayed
      enhancement scan and main cardiovascular events concluding recurrent myocardial infarction,
      cardiac death, recurrent angina, acute heart failure. Secondary end point of the study was
      the change of LVEF. All adverse clinical events as well as study end points were monitored
      and adjudicated by the independent event committee. Each patient was contacted in every week
      after administration of the contrast, investigated main cardiovascular events (myocardial
      infarction,acute heart failure and death), and record any adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TIMI flow grade</measure>
    <time_frame>immediately post procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarct size according to MR delayed enhancement scan</measure>
    <time_frame>3 to 5 days after PCI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>main cardiovascular events</measure>
    <time_frame>follow up in one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of the LVEF</measure>
    <time_frame>follow up in one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Trimetazidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimetazidine 60 mg 30 min before PCI and 20 mg for 12 months after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>placebo 60 mg 30 min before PCI and 20 mg for 12 months after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine</intervention_name>
    <description>Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery</description>
    <arm_group_label>Trimetazidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI patients: typical chest pain lasting 30 min within the previous 12 h, a clear
             ST-segment elevation of N0.1 mV in ≥2 contiguous electrocardiographic leads, and
             elevated blood levels of troponin T

          -  patients were scheduled to undergo diagnostic cardiac angiography or percutaneous
             coronary interventions

        Exclusion Criteria:

          -  The combined use of trimetazidine contraindications;

          -  had cardiogenic shock,

          -  had a history of myocardial infarction, stent thrombosis, or renal insufficiency;

          -  had previously undergone coronary artery bypass surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dai Yun Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li J, Li X, Wang Q, Hu S, Wang Y, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet. 2015 Jan 31;385(9966):441-51. doi: 10.1016/S0140-6736(14)60921-1. Epub 2014 Jun 23. Retraction in: Lancet. 2015 Jan 31;385(9966):402.</citation>
    <PMID>24969506</PMID>
  </reference>
  <reference>
    <citation>Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010 Jan;90(1):207-58. doi: 10.1152/physrev.00015.2009. Review.</citation>
    <PMID>20086077</PMID>
  </reference>
  <reference>
    <citation>Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17;86(5):580-8.</citation>
    <PMID>10720420</PMID>
  </reference>
  <reference>
    <citation>El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, Feuvray D. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res. 2000 Sep;47(4):688-96.</citation>
    <PMID>10974217</PMID>
  </reference>
  <reference>
    <citation>Chen J, Zhou S, Jin J, Tian F, Han Y, Wang J, Liu J, Chen Y. Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study. Int J Cardiol. 2014 Jul 1;174(3):634-9. doi: 10.1016/j.ijcard.2014.04.168. Epub 2014 Apr 21.</citation>
    <PMID>24809921</PMID>
  </reference>
  <reference>
    <citation>Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, Paganelli F. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart. 2007 Jun;93(6):703-7. Epub 2007 May 8.</citation>
    <PMID>17488771</PMID>
  </reference>
  <reference>
    <citation>Kim JS, Kim CH, Chun KJ, Kim JH, Park YH, Kim J, Choi JH, Lee SH, Kim EJ, Yu DG, Ahn EY, Jeong MH. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry. Clin Res Cardiol. 2013 Dec;102(12):915-22. doi: 10.1007/s00392-013-0611-0. Epub 2013 Aug 28.</citation>
    <PMID>23982468</PMID>
  </reference>
  <reference>
    <citation>El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5(4):271-8.</citation>
    <PMID>15984909</PMID>
  </reference>
  <reference>
    <citation>Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007 Nov;50(5):585-9.</citation>
    <PMID>18030070</PMID>
  </reference>
  <reference>
    <citation>Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011 Feb;97(4):278-86. doi: 10.1136/hrt.2010.208751. Epub 2010 Dec 5. Review.</citation>
    <PMID>21134903</PMID>
  </reference>
  <reference>
    <citation>Güler N, Eryonucu B, Günes A, Güntekin U, Tuncer M, Ozbek H. Effects of trimetazidine on submaximal exercise test in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 2003 Jul;17(4):371-4.</citation>
    <PMID>14696632</PMID>
  </reference>
  <reference>
    <citation>Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2008 Oct;15(5):533-40. doi: 10.1097/HJR.0b013e328304feec.</citation>
    <PMID>18797405</PMID>
  </reference>
  <reference>
    <citation>Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol. 2008 Oct;6(4):282-91. Review.</citation>
    <PMID>18855716</PMID>
  </reference>
  <reference>
    <citation>Jogiya R, Kozerke S, Morton G, De Silva K, Redwood S, Perera D, Nagel E, Plein S. Validation of dynamic 3-dimensional whole heart magnetic resonance myocardial perfusion imaging against fractional flow reserve for the detection of significant coronary artery disease. J Am Coll Cardiol. 2012 Aug 21;60(8):756-65. doi: 10.1016/j.jacc.2012.02.075. Epub 2012 Jul 18.</citation>
    <PMID>22818072</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Qian geng</investigator_full_name>
    <investigator_title>Chinese People's Liberation Army General Hospital</investigator_title>
  </responsible_party>
  <keyword>Trimetazidine</keyword>
  <keyword>ST-segment elevation myocardial</keyword>
  <keyword>Reperfusion injury</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

